Drug Trial Radar · NCT06584071
A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
Last checked: Nov 19, 2026Latest source record: Dec 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Dec 2024
Primary completion
Oct 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Biotheus Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study to evaluate the preliminary efficacy, safety and pharmacokinetics of PM8002 combined with PM1009 in Patients with first-line Hepatocellular Carcinoma.
Conditions
- HCC
- Liver Cancer
Interventions
PM8002Drug
PM8002 via IV infusion, Q3W
PM1009Drug
PM8002 via IV infusion, Q3W
atezolizumabDrug
atezolizumab,1200mg, via IV infusion, Q3W
bevacizumabDrug
bevacizumab,15mg/kg, via IV infusion, Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate(ORR)Time frame: Up to approximately 2 years
- Optimal dosing regimen of PM8002 in combination with PM1009Time frame: Up to approximately 2 years
- Treatment related adverse events (TRAEs)Time frame: Up to 30 days after last treatment
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.